Viewing Study NCT05683704


Ignite Creation Date: 2025-12-24 @ 9:09 PM
Ignite Modification Date: 2025-12-31 @ 12:50 AM
Study NCT ID: NCT05683704
Status: ENROLLING_BY_INVITATION
Last Update Posted: 2023-01-13
First Post: 2023-01-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module